T1	p 42 48	humans
T2	p 335 357	healthy young subjects
T3	p 431 461	Five groups of 8 subjects each
T4	p 1607 1615	with low
T5	p 1689 1704	atherosclerosis
T6	i 83 88	ester
T7	i 181 222	potent cholesteryl ester transfer protein
T8	i 232 255	inhibitor torcetrapib (
T9	i 278 302	high-density lipoprotein
T10	i 481 519	placebo ( n=2 ) or torcetrapib ( n=6 )
T11	i 542 554	120 mg daily
T12	i 559 565	120 mg
T13	i 592 603	Torcetrapib
T14	o 27 38	lipoprotein
T15	o 278 331	high-density lipoprotein cholesterol ( HDL-C ) levels
T16	o 613 622	tolerated
T17	o 690 727	of plasma drug levels with inhibition
T18	o 963 982	elevations of HDL-C
T19	o 1001 1025	Total plasma cholesterol
T20	o 1129 1164	low-density lipoprotein cholesterol
T21	o 1187 1211	Apolipoprotein A-I and E
T22	o 1345 1361	and triglyceride
T23	o 1379 1401	nonHDL plasma fraction
T24	o 1442 1445	HDL